Fusidic acid
As of the edition of 20 October 2026, Fusidic acid is a small molecule: marketed, first approved in 1984 (CA).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Fucidin
- First approved
- 31 December 1984 (CA)
- Approvals on record
- 7 in 4 regions
- Holder of the most recent approval
- LEO Pharma; 4 holders in all
- Registered trials
- 11, 2 stopped early
- Disease areas
- Skin and connective tissue; Infections; Bones, joints and muscles; Cancer; Eye; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 5 | 3 | 2 | 0 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| LEO Pharma | Applicant and Lead sponsor of trials | 1984 to now |